PMID: 2512048Jul 1, 1989Paper

In vitro comparison of cefpirome and four other beta-lactam antibiotics alone and in combination with tobramycin against clinical isolates of Pseudomonas aeruginosa

Diagnostic Microbiology and Infectious Disease
I CabezudoR Wenzel

Abstract

In vitro susceptibility studies of cefpirome versus cefotaxime, ceftazidime, imipenem, and piperacillin alone and in combination with tobramycin were performed against 153 clinical isolates of Pseudomonas aeruginosa from four medical centers. The minimal inhibitory concentration (MIC) for each antibiotic alone was determined by a standardized dilution method. Antibiotic combination studies were performed using a modified checkerboard technique. Cefpirome alone was more active (MIC90 64 micrograms/ml) than piperacillin (MIC90 128 micrograms/ml) or cefotaxime (MIC90 256 micrograms/ml) but less active than imipenem (MIC90 2 micrograms/ml) or ceftazidime (MIC90 32 micrograms/ml). The addition of tobramycin reduced the MICs of all of the beta-lactam antibiotics except for imipenem. The MIC90 for cefpirome when combined with tobramycin was 8 micrograms/ml compared to 16 micrograms/ml for cefotaxime and piperacillin, 8 micrograms/ml for ceftazidime, and 4 micrograms/ml for imipenem. The combination of tobramycin and cefpirome proved to be additive or synergistic for 82% of the isolates (highest rate) compared to 31% with imipenem (lowest rate). The potent in vitro antipseudomonal activity of cefpirome alone and in combination with an ...Continue Reading

References

Jan 1, 1979·European Journal of Cancer : Official Journal for European Organization for Research and Treatment of Cancer (EORTC) [and] European Association for Cancer Research (EACR)·J Klastersky
Jan 1, 1978·Chemotherapy·E T AndersonW L Hewitt
Feb 1, 1978·The Journal of Infectious Diseases·M C Berenbaum
Aug 1, 1976·Antimicrobial Agents and Chemotherapy·T C Eickhoff, J M Ehret
Feb 1, 1986·European Journal of Clinical Microbiology·I BravenyD Milatovic
Jun 1, 1985·The Journal of Antimicrobial Chemotherapy·A Bauernfeind
Sep 1, 1985·Archives of Internal Medicine·G P BodeyL Elting
Dec 1, 1985·Burns, Including Thermal Injury·J M ConlyA R Ronald
Jan 1, 1985·Archives of Oto-rhino-laryngology·K TanakaY Terayama
Mar 1, 1983·Reviews of Infectious Diseases·G P BodeyL Jadeja
Sep 1, 1984·Reviews of Infectious Diseases·L S Young
Sep 1, 1984·Reviews of Infectious Diseases·A J Morrison, R P Wenzel
Oct 1, 1984·Antimicrobial Agents and Chemotherapy·T M HootonG W Counts
Jun 1, 1984·Antimicrobial Agents and Chemotherapy·R N JonesA L Barry
Mar 1, 1982·Reviews of Infectious Diseases·J Klastersky, S H Zinner

❮ Previous
Next ❯

Citations

Mar 7, 2019·Nature Reviews. Microbiology·Karen Bush, Patricia A Bradford

❮ Previous
Next ❯

Related Concepts

Related Feeds

Antimicrobial Resistance

Antimicrobial resistance poses a significant threat to the continued successful use of antimicrobial agents for the treatment of bacterial infections.

Allergy & Infectious Diseases

Allergies result from the hyperreactivity of the immune system to some environmental substance and can be life-threatening. Infectious diseases are caused by organisms including bacteria, viruses, fungi and parasites. They can be transmitted different ways, such as person-to-person. Here is the latest research on allergy and infectious diseases.

Antimicrobial Resistance (ASM)

Antimicrobial resistance poses a significant threat to the continued successful use of antimicrobial agents for the treatment of bacterial infections.

Allergy & Infectious Diseases (ASM)

Allergies result from the hyperreactivity of the immune system to some environmental substance and can be life-threatening. Infectious diseases are caused by organisms including bacteria, viruses, fungi and parasites. They can be transmitted different ways, such as person-to-person. Here is the latest research on allergy and infectious diseases.